Due to the COVID-19 pandemic, the bladder cancer assessment will be paused now, to resume in 2-3 months.
ICER plans to assess the comparative clinical effectiveness and value of nadofaragene firadenovec (Instiladrin®, FKD Therapies Oy and Ferring Pharmaceuticals) for the treatment of bladder cancer. Nadofaragene firadenovec has received a fast track and breakthrough therapy designation from the FDA, with an anticipated decision expected in mid-2020.
Review date: November 2020
For more information, please contact Maggie O’Grady, Program Manager, at firstname.lastname@example.org.